Introduction
============

Although several targeted agents are implicated in the therapy of breast cancer (BC), traditional cytotoxic chemotherapy remains a mainstay of treatment ([@B52]; [@B50]). Neoadjuvant chemotherapy, initially used for the treatment of locally advanced and inoperable tumor, becomes an established therapeutic option for operable BC ([@B20]). Neoadjuvant chemotherapy improves the outcome of patients treated with surgery ([@B48]; [@B15]). After treatment, response to neoadjuvant chemotherapy is evaluated histologically in the surgical specimen. Pathological complete response (pCR), defined as the complete disappearance of invasive tumor cells in breast and axillary lymph nodes, to neoadjuvant therapy is an effective predictor of tumor progression ([@B15]; [@B52]), and patients whose tumors show pCR have a better clinical outcome compared to those with residual disease (RD) in the tumor ([@B3]; [@B47]; [@B37]). Unfortunately, there is a considerable proportion of high risk BC patients who do not respond to neoadjuvant chemotherapy ([@B4]; [@B49]). Therefore, it is of clinical interest to identify useful biomarker(s) to predict pCR to neoadjuvant chemotherapy, aiming to stratify patients for an optimal therapy. Studies over the years have indicated that clinic-pathological features including histologic grade and estrogen receptor (ER) status ([@B40]; [@B17]), and gene expression profiles related to cell proliferation ([@B43]) and cell cycle ([@B54]) are associated with pCR. Tumor prognostic expression values based on the Gene Expression Grade Index (GGI) ([@B44]), Oncotype Dx ([@B33]) and Gene70 signature ([@B51]) are positively correlated with the pCR probability ([@B11]; [@B24]). However, due to the heterogenicity of BC, different BC molecular subtypes classified through PAM50 signatures respond differently to chemotherapy ([@B39]; [@B35]).

Accumulating studies have suggested that dysregulated long non-coding RNAs (lncRNAs) were associated with tumorigenesis and progression in a variety of human cancers ([@B30]; [@B12]). LncRNAs, RNA transcripts range from 200 nucleotides to multiple kilobases in length, lack significant protein-coding capacity ([@B25]). Studies over the years have demonstrated that some dysregulated lncRNAs may contribute as tumor suppressors, while others may serve as proto-oncogenes and/or drivers of metastatic transformation in BC ([@B32]; [@B13]; [@B42]). It has been shown that lncRNA *HOTAIR* is overexpressed in BC, which might be associated with poor prognosis and high probability of metastasis ([@B13]). The overexpression of lncRNA *LSINCT5* is associated with BC cell proliferation and tumor development ([@B42]). On the other hand, overexpression of lncRNA *GAS5* (growth arrest-specific transcript 5) in MCF-7 BC cells induces apoptosis and growth arrest ([@B32]). These data collectively suggest that lncRNAs may play a critical role in tumor development and progression and be utilized as biomarker(s) for tumor diagnosis and prognosis.

As the data mining method of repurposing publicly available microarray datasets for lncRNA expression is well-developed ([@B9]; [@B10]), new cancer biomarkers for prognosis prediction by making full use of the re-annotated previous microarray datasets have been identified ([@B16]; [@B59]), and lncRNA signatures have been developed to predict overall survival ([@B29]) and metastasis-free survival ([@B46]) of BC patients. Recently, an lncRNA signature composed of 36 lncRNAs has been reported to serve as a biomarker for predicting pCR to neoadjuvant chemotherapy in breast cancer while the biological functions of these lncRNAs have not been explored ([@B53]).

To identify an effective but concise prognostic lncRNA biomarker for pCR to neoadjuvant chemotherapy in BC patients, we have mined the available gene expression microarray data from the Gene Expression Omnibus (GEO) and profiled the lncRNA expression data in the present study. By using logistic regression analysis, we identified a three-lncRNA signature that was associated to pCR to neoadjuvant chemotherapy. Moreover, we demonstrated the *BC032585*, one of the three lncRNAs, was directly linked to BC cell sensitivity to chemotherapy. These results suggest that a simple three-lncRNA signature may effectively serve as a predictive biomarker for pCR to neoadjuvant chemotherapy in breast cancer.

Materials and Methods {#s1}
=====================

Microarray Data Processing and LncRNA Profile Mining
----------------------------------------------------

Five datasets that contain genome-wide gene expression profiling data by using pretreatment biopsies from patients receiving neoadjuvant chemotherapy and corresponding clinical data were download from the GEO databases^[1](#fn01){ref-type="fn"}^. After removal of the samples without pathological drug response information, a total of 1102 patients were analyzed, including 488 from GSE25066 ([@B15]), 278 from GSE20194 ([@B41]), 178 from GSE20271 ([@B48]), 97 from GSE22093 ([@B18]), and 61 from GSE23988 ([@B18]). Primary analysis was conducted on dataset GSE25066. The other four datasets were combined and utilized for validation. The demographic characteristics of patients were listed in [Table 1](#T1){ref-type="table"}.

###### 

Patients' characteristics of the five datasets.

  Characteristics                    Training dataset   Validating dataset
  ---------------------------------- ------------------ --------------------
  **Sample size**                    488                614
  **Age, years**                                        
  ≤50                                268                316
  \>50                               220                296
  Unknown                            0                  2
  **Histologic grade**                                  
  1                                  29                 32
  2                                  172                213
  3                                  252                306
  Unknown                            35                 63
  **Nodal status**                                      
  Positive                           334                385
  Negative                           154                180
  Unknown                            0                  49
  **ER**                                                
  Positive                           285                338
  Negative                           197                275
  Unknown                            6                  1
  **Response**                                          
  pCR                                99                 130
  RD                                 389                484
  **Neoadjuvant Therapy Regimens**                      
  TA                                 488                0
  FAC                                0                  184
  TFAC                               0                  430

ER, estrogen receptor; TA, taxane and anthracycline; TFAC, taxane, 5-fluorouracil, anthracycline, and cytoxan; FAC, 5-fluorouracil, anthracycline, and cytoxan. pCR, pathological complete response; RD, residual disease.

The raw CEL files were downloaded from GEO, all gene expression data were generated with Affymetrix U133A gene chips and normalized with RMA algorithm using the 'affy' R package. GATExplorer was used to process microarrays for gene expressions of lncRNAs ([@B38]). GATExplorer provides a series of R packages called ncRNA Mapper, including the probes that are not assigned to mRNAs but mapped to a database for human non-coding RNA sequences derived from RNAdb ([@B34]). Each lncRNA should include no less than three probes mapping in the corresponding ncRNA entity. Expressions were calculated according to the re-mapping annotation file (ncrnamapperhgu133acdf) ([@B38]).

Molecular Classification of BC Subtypes
---------------------------------------

Breast cancer patients were divided into basal-like, luminal A, human epidermal growth factor receptor 2 (HER2) enriched, luminal B, and normal molecular subtypes based on the PAM50 algorithm ([@B35]) via the "genefu" R package. Samples classified into basal-like, HER2+, luminal A, and luminal B subtypes were included in subtype-based analysis.

Statistical Analysis of Bioinformatic Data
------------------------------------------

Statistical computations were performed using the R statistical software version 3.1.0 (R [@B6]) with related packages.

A univariate logistic regression analysis was performed to assess the association between the continuous expression level of each lncRNA and pCR in the training dataset. Expressions of five lncRNAs were identified to be strongly correlated with pCR (Bonferroni *p*-value \< 0.01). These five lncRNAs were further analyzed using a multivariable logistic regression model and only three lncRNA expression were found to be significantly associated with pCR (*p*-value \< 0.05). For the selection of most predictive model, we evaluated and compared the predictive ability of logistic regression and other four machine learning techniques, namely artificial neural network, regression tree, multivariate adaptive regression splines and Bayesian additive regression trees. The models generated by logistic regression and artificial neural network were outperformed the other approaches in the validating datasets according to the ROC analysis ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). We therefore selected the logistic regression model since it is easier to be understood and implemented in the clinics. A predictive score was then computed according to the formula:
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Where, *n* devotes for the number of prognostic lncRNAs in the model, *Exp*~i~ is the expression level of lncRNA~i~, and *Coe*~i~ is the estimated regression coefficient of lncRNA~i~ in the *i* multivariable logistic regression model. Patients with higher predictive scores are expected to have higher probability of pCR. Furthermore, multivariate logistic analyses were conducted to test whether the predictive score was independent of ER status, pathological grade and PAM50 molecular subtype.

We used receiver operating characteristic (ROC) curves to compare the sensitivity and specificity of molecular signatures used for the prediction of pCR. The area under the receiver operating characteristic curve (AUC) was calculated using the R-package ROCR. The differences between AUCs were tested with *z*-statistical method via the R-package pROC. The performance of the three-lncRNA predictive score developed in this study was compared to other available signatures, including GGI ([@B44]), Gene70 ([@B33]) and Oncotype Dx ([@B51]). The scores of GGI, Gene70, and Oncotype DX, calculated with "genefu" R package, were utilized as predictors for drawing ROC curves.

Co-expression Module Detection and Functional Annotation
--------------------------------------------------------

Co-expression modules were identified with weighted gene co-expression network analysis (WGCNA) ([@B56]). The co-expressed relationships between the prognostic lncRNAs and module eigenvalues (MEs) of the modules were computed using Pearson's correlation coefficients. Gene ontology (GO) biological process enrichment analyses of the modules co-expressed with prognostic lncRNAs were performed to predict the biological function of prognostic lncRNAs via the DAVID annotation tool^[2](#fn02){ref-type="fn"}^ with the functional annotation clustering option.

Before WGCNA analysis, all gene expression data were normalized with the RMA algorithm using the 'affy' R Bioconductor package. Probe sets without known gene symbols were filtered and probe-level expression profiles were converted into gene-based expressions through probe merging with the collapseRows function ([@B31]). We adjusted the gene expression levels of entire dataset, which consists of five datasets for potential batch effects, with the ComBat algorithm ([@B19]). WGCNA ([@B56]) was performed with the "wgcna" R package ([@B23]). A co-expression network was constructed based on 3,600 genes selected based on the following criteria: (i) 5,000 genes with the highest expression variance across the data set; and (ii) the 3,600 genes with the highest degree of co-expression (based on k.total of WGCNA) from the 5,000 genes. To summarize the relationship between all possible pairs of the selected genes, a Pearson's correlation coefficient was calculated. The correlation matrix was raised to the power 5 and thus producing a weighted network, [k.total]{.ul} of a gene was defined as the sum of its adjacency with all other genes for network generation. The topological overlap measure (TOM) was utilized to measure the co-expression similarity for each gene pair from the weighted network. This advanced co-expression measure considers not only the relationship between two genes with each other, but also the extent of their shared connections across the weighted network. We used a hierarchical clustering with dissimilarity based on 1-TOM to produce a hierarchical clustering tree of genes. Modules were identified on the dendrogram using the Dynamic Tree Cut algorithm with a height cutoff of 0.95 and a gene number cutoff of 30 ([@B27]). To assess the potential correlation of gene modules with the expression levels of lncRNAs, a summary profile of each module, called the ME that corresponds to the first principal component of the module was calculated. The WGCNA method has been described in detail by [@B56].

Reagents
--------

Doxorubicin (DOX) was purchased from Sigma-Aldrich (St. Louis, MO, United States) and paclitaxel (PTX) from Meilunbio (Dalian, China). Drugs were dissolved in 100% dimethyl sulfoxide (DMSO) as stock solutions. Dilutions for all drug treatments were made extemporaneously in culture medium, so that the final concentration of DMSO never exceeded 0.1% (v/v).

Cell Culture
------------

Human breast cancer MDA-MB-231 cells and MCF-7 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, United States). Cells were routinely maintained in RPMI-1640 medium (Gibco, Grand Island, NY, United States) containing 10% FBS (BI Technologies, Fullerton, CA, United States), 20 mM [L]{.smallcaps}-glutamine (Sigma-Aldrich), 100 U/ml of penicillin (BI Technologies) and 100 μg/ml of streptomycin (BI Technologies) at 37°C in a 5% CO2-95% air humidified atmosphere. The medium was changed every other day.

Transfection of siRNAs
----------------------

Three small-interfering RNA (siRNA-1, -2, -3) against *BC032585* gene and a scrambled control small interfering RNA (siRNA) were purchased from RiboBio (Guangzhou, China). The transfection of siRNAs was conducted as previously described ([@B60]). Briefly, approximately 3 × 10^5^ cells suspended in 2 ml experimental medium \[a mixture of phenol red-free RPMI-1640 medium supplemented with 5% charcoal-dextran-treated FBS (BI Technologies) and 20 mM [L]{.smallcaps}-glutamine\] were added in each well of 6-well plate. After incubated overnight, 245 μl Opti-MEM medium containing 7.5 μl Lipofectamine RNAiMAX was mixed with a 245 μl Opti-MEM medium containing 10 μl siRNA, and the mixture added to 1.5 ml experimental medium was dripped into each well of 6 well plate. The final concentration of siRNA was 100 nM, a common concentration used in cell culture study ([@B21]; [@B36]). After 24 h incubation at 37°C, the medium was discarded, and the cells were incubated with fresh experimental medium. The sequences of siRNAs were summarized in [Supplementary Table S1](#SM1){ref-type="supplementary-material"}. The knockdown efficiency was tested by quantitative RT-PCR at 48--72 h after transfection.

RNA Extraction and Quantitative Real Time (qRT)-PCR
---------------------------------------------------

Total RNA extraction and qRT-PCR were performed as previously described ([@B45]). Briefly, total cellular RNA was isolated from harvested cells using the Total RNA Kit II (Omega Bio-Tek, Inc., Norcross, GA, United States) according to the manufacturer's instruction. First-strand cDNA was generated by reverse-transcription using random primers with the Prime Script RT reagent Kit with gDNA Eraser (TaKaRa BIOTECHNOLOGY, Dalian, China) in a 20 μl reaction containing 0.5--1 μg of total RNAs. The real-time PCR was performed on LightCycler 480 Sequence Detection System using the SYBR Green Realtime PCR Master Mix assay kit (TaKaRa). Reaction parameters were: 95°C for 30 s; then 95°C for 5 s, 55°C for 1 min, and 72°C for 30 s with a cutoff of 45 cycles. Relative gene expression was calculated using the 2^-(ΔΔCT)^ method with β-actin as a reference gene. The primers used were: BC032585, 5′-GCTCTGACAATGTTGTGCTGG-3′ and 5′-GAGTGCTCAAAGTCACACGC-3′; AK291479, 5′-TGACT CTGTGGTTCATTCTGGT-3′ and 5′-CCATCCCCAAGTCAG GAACC-3′; U79293 5′-CTTCTGCTGCTGCTTGGAGT-3′ and 5′-AAGCTCGCCACTCATGACAG-3′; β-actin, 5′-TCAAGATCATTGCTCCTCCTGAG-3′ and 5′-ACATCTGCTGGAAG GTGGACA-3′.

Cell Proliferation Assay
------------------------

Cell proliferation assay was performed to detect cell viability using a cell proliferation assay Kit from Promega (Madison, WI, United States) as described previously ([@B45]). Briefly, cells transfected for 24 h with either control or *BC032585* siRNA were passaged to 96-well plates at 5 × 10^3^ cells/well in experimental medium and grown at 37°C for 24 h before drug administration. The cells were then treated with 100 μl of fresh experimental medium containing various concentrations of doxorubicin, paclitaxel or both for 48 h as indicated in each experiment. At the end of experiment, the viable cell number were determined using the Promega assay kit according to the manufacturer's instruction, and the optical absorbance was determined at 490 nm in a microplate reader. The viability ratio was calculated according to the following formula: the viability ratio = \[(the absorbance of experimental group - the absorbance of blank group)/(the absorbance of untreated group - the absorbance of blank group)\] × 100%.

Western Blotting
----------------

The level of MDR1 was determined using Western blotting as we previously described ([@B45]). Briefly, total proteins were extracted from cells treated with 100 nM siRNA for 48 and 96 h, and quantified using a BCA Protein Assay Kit following the manufacturer's instruction (TianGEN, China). A total of 50 μg proteins was denatured, loaded into an 8% SDS-PAGE, electrophoresed and transferred to PVDF membranes. The membrane was blocked in TBST buffer containing 5% non-fat milk for 2 h at room temperature, and then washed with TBST buffer and incubated with a specific primary antibody against MDR1 (1:1000; ab170904, Abcam, United States) or β-actin (1:5000; AC-15, Sigma, United States) at 4°C for 16 h. Following the corresponding secondary antibody incubation for 1 h at room temperature, the signal was visualized using the enhanced chemiluminescence detection system and quantitated under the Bio-Rad ChemiDoc MP system. β-actin was used as a loading control. Each experiment was repeated at least three times.

Statistical Analysis of Experiment
----------------------------------

Statistical analysis was carried out using GraphPad Prism 6 applying Student's *t*-test for RT-qPCR or western blot comparisons (mRNA or protein expression levels) or 2-way ANOVA test for cell viability comparison. All statistical tests were two-sided and *p* \< 0.05 was considered statistically significant.

Results
=======

A Three-LncRNA Signature Is Identified to Be Associated With pCR in BC Patients
-------------------------------------------------------------------------------

As summarized in the workflow diagram ([Figure 1](#F1){ref-type="fig"}), all initial analyses were performed in the training set and validated in the test set. The training set with 488 BC patients was utilized for the detection of potential lncRNAs that were associated with pCR of chemotherapy. By subjecting the lncRNA expression data of the test series to univariate logistic regression, we identified a set of five lncRNAs that were significantly correlated with patients' pCR (Bonferroni *P* \< 0.05; [Supplementary Table S2](#SM1){ref-type="supplementary-material"}). Three of the five lncRNAs remained significant correlation with pCR following the analysis by multivariable logistic regression model ([Table 2](#T2){ref-type="table"}). A positive coefficient in regression analysis for lncRNA *AK291479* and *BC032585* was obtained, indicating that an elevated expression of this lncRNA is associated with a high probability of pCR. In contrast, a negative coefficient for lncRNA *U79293* was observed, indicating that a high expression of *U79293* is associated with a low probability of pCR.

![Diagram of the study. Develop predictive model for pCR and validate the efficiency of the lncRNA signature to predict pCR. LR, logistic regression; ANN, artificial neural network; RT, regression tree; MDR, multivariate adaptive regression splines; BART, Bayesian additive regression trees; pCR, pathological complete response; ROC, receiver operating characteristic.](fphar-10-00574-g001){#F1}

###### 

Association of three lncRNAs with pCR in breast cancer patients treated with neoadjuvant chemotherapy in the training dataset (*n* = 488).

  Position                    Gene symbol   Univariate analysis   Multivariate Logistic regression                                             
  --------------------------- ------------- --------------------- ---------------------------------- --------------- --------------- --------- ---------------
  chrX: 104072568-104076212   *AK291479*    2.27                  1.74--2.99                         2.87 × 10^-9^   2.00 × 10^-6^   0.5297    4.39 × 10^-4^
  chr15: 71293150-71294925    *U79293*      0.19                  0.10--0.35                         5.13 × 10^-7^   3.58 × 10^-4^   -1.1409   7.83 × 10^-4^
  chr9: 37883335-37884282     *BC032585*    4.02                  2.14--7.64                         1.75 × 10^-5^   1.22 × 10^-2^   0.8039    2.48 × 10^-2^

In order to choose the most suitable algorithms for predictive model, ROCs for logistic regression, artificial neural network, regression tree, multivariate adaptive regression splines and Bayesian additive regression trees were generated as shown in [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}. Although the predictive values of regression tree and Bayesian in the training analysis were better than others, the predictive ability using models of logistic regression and artificial neural network (AUC = 0.73) was outperformed the other approaches in the validating dataset ([Supplementary Figure S1B](#SM1){ref-type="supplementary-material"}). We selected the logistic regression model for subsequent analysis as it is easy to be understood and implicated in clinical practice. Based on the expression of the three identified lncRNAs, a formula was generated for the prediction of pCR: Predictive score = 0.5297^∗^ (expression level of *AK291479*) +0.8039^∗^ (expression level of *BC032585*) -1.1409^∗^ (expression level of *U79293*). This predictive score was able to successfully distinguish between pCR and residual disease (RD) with an AUC value of 0.74, 0.72, and 0.73 in the training, validating and entire dataset, respectively ([Figure 2A,B](#F2){ref-type="fig"}). The predictive value of this lncRNA signature was variant in cohorts treated with different chemotherapeutic regimens. The AUC values of the predictive score were 0.75, 0.74, and 0.68 for patients treated with TA (taxane and anthracycline), TFAC (taxane, 5-fluorouracil, anthracycline, and cytoxan) and FAC (5-fluorouracil, anthracycline, and cytoxan), respectively ([Figure 2C](#F2){ref-type="fig"}), suggesting that this lncRNA signature may be more valuable in predicting anthracycline-based chemotherapeutic response. However, the clinical significance of this predictive score remains to be validated in future clinical trials.

![Unsupervised clustering heatmaps and ROC curves for the three lncRNA signature. **(A)** Heatmaps based on 3 lncRNAs (rows) of patients with breast cancer (columns) in the whole datasets (*n* = 1102). Red and blue indicate high and low expression, respectively. ROC curves assess the accuracy of the lncRNA signatures in different datasets **(B)** and for breast cancer patients treated with different chemotherapy regimens: TA, taxane and anthracycline; TFAC, taxane; 5-fluorouracil, anthracycline, and cytoxan; and FAC, 5-fluorouracil, anthracycline, and cytoxan **(C)**. True positive rate represents module sensitivity, whereas false positive rate is one minus the specificity.](fphar-10-00574-g002){#F2}

The Three-LncRNA Signature Is an Independent Predictor of pCR in BC Patients
----------------------------------------------------------------------------

To ascertain whether this three-lncRNA signature is an independent predictor of pCR in BC patients, we first identified that lncRNA predictive score, histological grade, ER status and PAM50 subtypes were associated with pCR using univariate logistic regression analysis ([Table 3](#T3){ref-type="table"}). Furthermore, multivariate logistic regression analysis revealed that the lncRNA predictive score was an independent predictor of pCR adjusted by grade, ER status and PAM50 molecular subtype in both the training (OR = 1.60, 95% CI = 1.06--2.44, *p* = 2.65 × 10^-2^) and validating cohort (OR = 1.83, 95% CI = 1.27--2.67, *p* = 1.33 × 10^-3^) as shown in [Table 3](#T3){ref-type="table"}. In other word, the prognostic ability of the three-lncRNA signature is significant even after accounting for clinicopathologic variables (grade, ER status and PAM50 molecular subtype).

###### 

Logistic regression models for pathological complete response in the training and testing datasets.

                                           Univariate model   Multivariate model                                         
  ---------------------------------------- ------------------ -------------------- ---------------- ------ ------------- ---------------
  **Training set**                                                                                                       
  lncRNA predictive score                  2.72               2.06--3.64           4.49 × 10^-12^   1.60   1.06--2.44    2.65 × 10^-2^
  **Grade (ref = 1)**                                                                                                    
  2                                        2.10               0.39--39.00          4.84 × 10^-1^    0.50   0.07--10.30   5.54 × 10^-1^
  3                                        12.32              2.56--221.60         1.44 × 10^-2^    1.51   0.20--31.29   7.25 × 10^-1^
  **ER (ref = negative)**                                                                                                
  Positive                                 0.22               0.14--0.36           8.38 × 10^-10^   0.82   0.35--1.87    6.41 × 10^-1^
  **PAM 50 subtypes (ref = Basal-like)**                                                                                 
  Her2+                                    0.43               0.16--0.98           5.83 × 10^-2^    0.50   0.13--1.53    2.57 × 10^-1^
  Luminal A                                0.06               0.02--0.14           4.51 × 10^-9^    0.26   0.06--0.95    5.12 × 10^-2^
  Luminal B                                0.34               0.16--0.65           1.96 × 10^-3^    0.92   0.32--2.69    8.85 × 10^-1^
  **Testing set**                                                                                                        
  lncRNA predictive score                  2.69               2.09--3.51           6.44 × 10^-14^   1.83   1.27--2.67    1.33 × 10^-3^
  **Grade (ref = 1)**                                                                                                    
  2                                        3.21               0.63--58.67          2.63 × 10^-1^    1.48   0.27--27.67   7.13 × 10^-1^
  3                                        13.95              2.93--250.25         1.00 × 10^-2^    2.75   0.51--51.32   3.42 × 10^-1^
  **ER (ref = negative)**                                                                                                
  positive                                 0.19               0.12--0.29           1.11 × 10^-13^   0.41   0.20--0.85    1.52 × 10^-2^
  **PAM 50 subtypes (ref = Basal-like)**                                                                                 
  Her2+                                    0.97               0.49--1.87           9.18 × 10^-1^    1.38   0.63--2.99    4.15 × 10^-1^
  Luminal A                                0.05               0.01--0.13           4.60 × 10^-7^    0.30   0.06--1.05    8.27 × 10^-2^
  Luminal B                                0.28               0.17--0.44           3.84 × 10^-8^    1.02   0.48--2.16    9.56 × 10^-1^

The Three-LncRNA Signature Is Equivalent to Other Molecular Signatures in Predicting pCR in BC Patients
-------------------------------------------------------------------------------------------------------

To compare the three-lncRNA signature to other molecular signatures in predicting pCR, ROC analyses were performed to evaluate the sensitivity and specificity of the lncRNA signature and three published tests, Oncotype DX ([Figure 3A](#F3){ref-type="fig"}), GGI ([Figure 3B](#F3){ref-type="fig"}), and Gene70 ([Figure 3C](#F3){ref-type="fig"}) in predicting pCR. Overall, all four signatures showed predictive power in distinguishing pCR from RD as their AUC values were above 0.5 ([Figure 3D](#F3){ref-type="fig"}). However, the three-lncRNA signature (AUC = 0.73) was significantly superior to GGI and Oncotype DX (AUC = 0.66, *p* \< 0.001) and equivalent to Gene70 (AUC = 0.71) as shown in [Figure 3D](#F3){ref-type="fig"}. In the TFAC chemotherapy group (*n* = 430), the performance of the lncRNA signature was outperformed GGI and Oncotype DX (*p* \< 0.05) but not Gene70. However, in the cohorts received chemotherapy regimen of TA (*n* = 488) or FAC (184), we found no significant difference (*p* \> 0.05) between our defined lncRNA signature and the three published tests ([Figure 3E,G](#F3){ref-type="fig"}), as demonstrated by the AUC values, due to the small sample size (184 in FAC).

![Unsupervised clustering heatmaps and ROC curves for publically available signatures. Heatmaps based on genes (rows) of patients with breast cancer (columns) for the Oncotype DX **(A)**, GGI **(B)**, and Gene70 **(C)** signatures. Red and blue indicate high and low expression, respectively. ROC curves assess the accuracy of the three-lncRNA, Oncotype DX, GGI and Gene70 signatures for all patients **(D)**, patients treated with TA (**E**, taxane and anthracycline), TFAC (**F**, taxane, 5-fluorouracil, anthracycline, and cytoxan) and FAC (**G**, 5-fluorouracil, anthracycline, and cytoxan). True positive rate represents module sensitivity, whereas false positive rate is one minus the specificity.](fphar-10-00574-g003){#F3}

Functional Annotation
---------------------

To further investigate the potential biological roles of the three prognostic lncRNAs, the co-expressed relationships between the three-lncRNA signature with the seven co-expression modules ([Figure 4A](#F4){ref-type="fig"}) identified by WGCNA were accessed via Pearson's correlation coefficients in the entire dataset ([Supplementary Table S3](#SM1){ref-type="supplementary-material"}). The module-red expression, which composes of 45 genes ([Supplementary Table S4](#SM1){ref-type="supplementary-material"}), was highly correlated with the predictive score generated from the three-lncRNA signature (*R* = 0.45, *p* \< 0.001, [Figure 4B](#F4){ref-type="fig"}). Moreover, Pearson correlation analysis of each dataset revealed a significant negative correlation between BC032585 and ABCB1 gene expression ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). GO function enrichment analysis of the module red by using the whole human genome as the background suggested that module red was significantly enriched in 34 GO terms (Bonferroni *p* \< 0.05, [Supplementary Table S5](#SM1){ref-type="supplementary-material"}). Among them, 14 terms were related to cell cycle/proliferation as shown in [Figure 4C](#F4){ref-type="fig"}, suggesting that the three-lncRNA signature might be involved in the regulation of cell proliferation through modulating protein-coding gene expression.

![Functional annotation of the three lncRNA signatures. **(A)** Hierarchical cluster analysis dendrogram was utilized to identify co-expression clusters with the gene profiler from the dataset with 1,102 patients with breast cancer treated with chemotherapy. In the picture, branches are presented as the co-expression modules with highly interconnected genes with different colors to indicate module assignment. **(B)** Scatter plot between the three-lncRNA signature and ME of module red. Significant positive correlation relationship between them (*R* = 0.45). **(C)** GO enrichment analysis for the 45 genes comprising the red modules presented multiple processes. The original significance reported by DAVID for GO biological processes were transformed to "--log (*p*-value)" for plotting.](fphar-10-00574-g004){#F4}

Effect of BC032585 LncRNA on Drug Sensitivity
---------------------------------------------

Based on the bioinformatics analysis, we observed that an increased expression of *AK291479* and *BC032585* lncRNA and/or a decreased expression of *U79293* lncRNA was associated with a high probability of pCR following neoadjuvant chemotherapy, i.e., a high sensitivity to chemotherapeutic agent(s). To verify this observation experimentally, we performed *in vitro* study to determine the cell sensitivity to chemotherapeutic agents, taxane and anthracyclines, in MDA-MB-231 (a triple negative BC cell line) and MCF-7 (an ER-positive) BC cells with or without an alteration in *BC032585* lncRNA expression. The *BC032585* lncRNA was selected since it has a relatively high expression in MDA-MB-231 cells compared to the other two lncRNAs ([Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). As shown in [Figure 5](#F5){ref-type="fig"}, the expression of *BC032585* lncRNA in MDA-MB-231 ([Figure 5A](#F5){ref-type="fig"}) and MCF-7 cells ([Figure 5B](#F5){ref-type="fig"}) was dramatically decreased more than 90% using RNA interference with 3 specific siRNAs. Two of the three siRNAs were selected to knockdown *BC032585* lncRNA level and the transfected cells were exposed to TA agents. After treatment for 48 h with 0.05, 0.1, 0.25, 0.5, and 1 μM DOX alone or in combination with 0.05 μM PTX, MDA-MB-231 cells transfected with *BC032585* siRNA-1 ([Figure 5C](#F5){ref-type="fig"}) or siRNA-3 ([Figure 5D](#F5){ref-type="fig"}) showed a significant resistance to chemotherapy, either DOX alone or in combination with PTX, compared to parallel control siRNA-treated cells. On the other hand, knockdown of *BC032585* had no significant effect on MDA-MB-231 cell sensitivity to PTX treatment ([Figure 5C,D](#F5){ref-type="fig"}). Furthermore, similar alternations in chemo-sensitivity to DOX and PTX treatment were observed in MCF-7 cells when *BC032585* was knocked down ([Figure 5E,F](#F5){ref-type="fig"}). These results collectively suggest that *BC032585* primarily regulates cell sensitivity to DOX but not to PTX.

![Knockdown of *BC032585* lncRNA increases cell resistance to chemotherapeutic agents in MDA-MB-231 and MCF-7 breast cancer cells. **(A,B)** MDA-MB-231 and MCF-7 cells were transfected with a specific *BC032585* siRNA (*BC032585* siRNA --1, 2, 3, and 100 nM), or a negative control siRNA (control siRNA) for 24, 48, and 72 h. The transfected cells were then harvested for quantification of *BC032585* lncRNA by real-time PCR. The RNA levels were expressed as fold of corresponding controls, and the data are mean ± SD of three independent experiment. ^∗∗∗^*p* \< 0.001 compared to the corresponding controls. **(C,D)** MDA-MB-231 cells were transfected with either *BC032585* siRNAs or control siRNA for 24 h, and then plated in 96-well plates and treated with various doses of DOX alone or in combination with 0.05 μM PTX for 48 h. The number of viable cells (cell viability) was determined at the end of treatment and expressed as a percentage of corresponding vehicle control. The data are the mean ± SEM of two or three independent triplicate experiments. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 compared to corresponding controls. **(E,F)** MCF-7 cells in 96-well plate were transfected with either *BC032585* siRNAs or control siRNA for 48 h and then treated with various doses of DOX alone or in combination with 0.05 μM PTX for another 48 h. The number of viable cells (cell viability) was determined at the end of treatment and expressed as a percentage of corresponding vehicle control. The data are the mean ± SEM of two or three independent triplicate experiments. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, ^∗∗∗∗^*p* \< 0.0001 compared to corresponding controls.](fphar-10-00574-g005){#F5}

To further investigate the mechanism of how *BC032585* lncRNA modulates the sensitivity of tumor cells to TA treatment, we examined MDR1 protein expression in MDA-MB-231 cells following *BC032585* knockdown as both DOX an PTX are substrates of MDR1, and MDR1 is known to confer resistance to a variety of anticancer agents including doxorubicin and paclitaxel ([@B1]; [@B5]). Furthermore, there was a significant negative correlation between *BC032585*and ABCB1 expression ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). Western blot analysis revealed that knockdown of *BC032585* by two specific siRNAs resulted in a significant elevation of the MDR1 protein level in MDA-MB-231 cells ([Figure 6](#F6){ref-type="fig"}). These results suggest that the effect of *BC032585* lncRNA on chemotherapeutic drug sensitivity is mediated, at least in part, through the upregulation of MDR1 expression in MDA-MB-231 cells.

![Knockdown of *BC032585* lncRNA increases MDR1 expression in MDA-MB-231 breast cancer cells. **(A,B)** MDA-MB-231 cells were transiently transfected with a specific *BC032585* siRNA (100 nM) or a control siRNA for 48 h **(A)** and 96 h **(B)**. The transfected cells were then harvested for quantification of MDR1 protein levels by Western blot analysis. β-actin was used as an internal loading control. The protein levels were expressed as fold of corresponding controls, and the data are mean ± SD of two or three independent experiments. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 compared to the corresponding control.](fphar-10-00574-g006){#F6}

Discussion
==========

Accumulating evidence in the study of dysregulated lncRNA expression across various cancer types indicate that lncRNAs play critical roles in tumorigenesis ([@B57]) through modifications of multiple cancer related biological processes such as apoptosis, cell cycle regulation and metastasis ([@B13]; [@B7]). Furthermore, these dysregulated lncRNAs could mark the spectrum of tumor progression with a great potential as novel independent molecular biomarkers for the diagnosis and prognosis of cancer ([@B16]; [@B29], [@B28], [@B26]). Recently, several studies have functionally characterized multiple pathogenesis-related lncRNAs in BC ([@B32]; [@B13]; [@B42]), but the prognostic value of these lncRNAs has been merely investigated ([@B29]; [@B46]). Recently, a 36-lncRNA signature has been reported to predict pCR to neoadjuvant chemotherapy in breast cancer patients ([@B53]), however, it did not perform experimental analysis of the functional significance of any identified lncRNA. To explore the prognostic value of lncRNAs in neoadjuvant chemotherapy, we have utilized microarray probe mining to repurpose the existing human Affymetrix microarray data (platform HG-U133A) and subsequently obtained lncRNA expression profiles of 1102 BC patients from GEO database. Using association analysis between lncRNA expression and pCR in breast cancer patients following neoadjuvant chemotherapy in the training dataset, a three-lncRNA signature has been identified to be independently associated with pCR, which is further confirmed in the validation dataset.

Following multivariable logistic regression analysis, we have revealed that the prognostic value of this three-lncRNA signature was independent of other main prognostic factors including estrogen receptor (ER) status, tumor grade and molecular subtypes. It has been reported that ER-negative and high-grade breast cancers were consistently associated with a better response to chemotherapy ([@B40]; [@B22]); and different molecular subtypes of breast cancers based on PAM50 classifier responded differently to neoadjuvant chemotherapy ([@B35]). Specifically, HER2 positive and basal-like subgroups are associated with the highest rates of pCR (about 45%), whereas the luminal tumors had a pCR rate of only 6% ([@B39]). In agreement with previous studies, we have observed that ER status, tumor grade and PAM50 molecular subtypes were significantly associated with pCR when evaluated by the univariate logistic regression analysis in both the training and validating datasets ([Table 3](#T3){ref-type="table"}). Moreover, we have demonstrated through multivariable logistic regression analysis that the three-lncRNA signature is an independent factor in the prediction of pCR in breast cancer patients treated with neoadjuvant chemotherapy ([Table 3](#T3){ref-type="table"}). Furthermore, we have found that the predictive power of this three-lncRNA signature is equivalent to that of PAM50 (AUC = 0.73), and higher than those of ER status (AUC = 0.69) and tumor grade (AUC = 0.68) as analyzed by ROC ([Supplementary Figure S4](#SM1){ref-type="supplementary-material"}, *p* \< 0.05). In addition, the predictive power, based on the AUC of ROC analysis ([Figure 3](#F3){ref-type="fig"}), of the current three-lncRNA signature is comparable or superior to three previously published molecular signatures: GGI, Gene 70, and Oncotype DX ([Figure 3](#F3){ref-type="fig"}). For patients treated with TFAC ([Figure 3F](#F3){ref-type="fig"}), the AUC of the three-lncRNA signature is higher than those of GGI, Gene70, and Oncotype DX (*p* \< 0.05). Meanwhile, compared to the three mRNA-profile based molecular signatures, which require to analyze hundreds of mRNAs, only three lncRNAs need to be quantitated in the current three-lncRNA signature to generate an equivalent or superior efficiency in predicting pCR in breast cancer patients treated with neoadjuvant chemotherapy. Taken together, the three-lncRNA signature identified in our current study may be a simple, efficient and economical biomarker for stratifying breast cancer patients in neoadjuvant chemotherapy.

It should be noted that the biological functions of these three lncRNAs have not been investigated. Interestingly, *AK291479* overlaps with the transcript of thymosin beta-15B (TMSB15B), one of the two isoforms of human thymosin beta 15, TMSB15A and TMSB15B, which show approximately equivalent levels of expression in MCF-7 breast cancer cells ([@B2]). Moreover, it has been reported that thymosin beta 15A (TMSB15A) is a predictor of pCR of chemotherapy in triple-negative breast cancer ([@B8]). WGCNA and gene functional annotation analysis suggest that these three lncRNAs are likely to involve in cell cycle and cell proliferation, cell features related to pCR ([@B44]).

To experimentally confirm the functional significance of the identified lncRNAs in drug sensitivity, we have studied the effect of *BC032585*, one of the three lncRNAs, on sensitivity to taxane and anthracyclines treatment in MDA-MB-231 and MCF-7 breast cancer cells. As expected, knockdown of *BC032585* lncRNA using specific siRNAs in the cells resulted in a cell resistance to the treatment of doxorubicin and doxorubicin plus paclitaxel, but not paclitaxel alone as accessed by cell viability ([Figure 5](#F5){ref-type="fig"}). These experimental results support our bioinformatic analyses that an increased expression of *BC032585* lncRNA is associated with a high probability of pCR following neoadjuvant chemotherapy (i.e., a high sensitivity to chemotherapy), and the three-lncRNA signature has a better predictive power in anthracycline-based chemotherapeutic response. Since anthracycline is a first-line chemotherapeutic agent for metastatic breast cancer ([@B14]), this three-lncRNA signature may serve as a potential biomarker for personalized chemotherapy in BC patients.

To explore the molecular mechanism of the identified lncRNAs on drug sensitivity, we determined MDR1 expression in MDA-MB-231 breast cancer cells transfected with specific siRNAs against *BC032585*, one of the three lncRNAs. Knockdown of *BC032585* significantly increased the MDR1 expression in MDA-MB-231 cells ([Figure 6](#F6){ref-type="fig"}). As MDR1 is a well-documented membrane drug efflux and responsible for multiple drug resistance including doxorubicin ([@B1]; [@B5]), the current data suggest that the *BC032585*-related drug sensitivity may be mediated, at least in part, through the regulation of MDR1 expression although the molecular mechanism of *BC032585* regulation of MDR1 expression remains to be elucidated. This observation also supports our previous demonstration that lncRNA-regulated MDR1 alteration is a critical pathway mediating chemoresistance in breast cancer cells ([@B60]).

How lncRNA *BC032585* regulates MDR1 expression is currently unclear. Previous studies have suggested that lncRNAs may regulate target gene expression through either *cis*- or *trans*-regulation. [@B55] have reported that lncRNA *UCA1* functioned as a competitive endogenous RNA (ceRNA) of *ABCB1* through completive binding of microRNA16 in chronic myeloid leukemia cells. [@B58] have shown that lncRNA *PVT1* could promote MDR1 expression through *mTOR/HIF-1a/P-gp* signaling pathway in gastric cancer cells, and our previous study have demonstrated that lncRNA H19 could regulate MDR1 expression through a *H19-CUL4A-MDR1* pathway in breast cancer cells ([@B60]). This data collectively suggests that lncRNA *BC032585* may regulate MDR1 expression through either a *cis*- or *trans*-regulatory mechanism, which is under investigation in our laboratory.

There are multiple limitations in the present study. First, despite a fraction of human lncRNAs (698 out of 20000+) were included in our analysis, GATExplorer was not available for use any more, which was the first system that integrates mapping of probes with genomic contextual views, as well as expression signals at probe level. By far, the most common lncRNA annotation platform is GENCODE, and the version of which is constantly updated. Second, although WGCNA and gene functional annotation analysis suggest that the three lncRNAs may involve in cell cycle and cell proliferation, functional analysis only performed for *BC032585* and the other two lncRNAs, *AK291479* and *U79293*, remain to be investigated. Moreover, the molecular mechanisms of these lncRNAs in modulation of drug sensitivity warrant further investigation, especially those factors associated with this lncRNA signature ([Supplementary Table S4](#SM1){ref-type="supplementary-material"}). Finally, next-generation sequencing technology has advantages over microarray and has been employed worldwide for molecular diagnostics and identifying predictors of chemosensitivity. Although we have identified and validated this three-lncRNA signature in four independent datasets, its clinical significance and application need further investigation including next-generation sequencing data analysis in prospective clinical trials.

Conclusion
==========

In summary, via probing and integrating publicly available microarray datasets, we have identified a three-lncRNA signature that is independently associated with pCR in breast cancer patients treated with neoadjuvant chemotherapy. Based on ROC analysis, this signature is comparable or superior to previously published molecular signatures and clinicopathological features in predicting pCR in breast cancer patients treated with neoadjuvant chemotherapy. Moreover, we have demonstrated that one of the three lncRNAs, *BC032585*, plays a significant role in cell sensitivity to chemotherapeutic agents presumably mediated through regulation of MDR1 expression. Taken together, these data indicate that this three-lncRNA signature may serve as a useful biomarker in stratifying advanced breast cancer patients in neoadjuvant chemotherapy, and as potential molecular targets for optimization of breast cancer chemotherapy.
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